GNLX
GNLX
NASDAQ · Biotechnology

Genelux Corp

$2.39
+0.04 (+1.70%)
As of Feb 8, 2:11 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 59.48M 62.40M 61.85M
Net Income -10,809,084 -13,759,336 -10,609,098
EPS
Profit Margin -18.2% -22.1% -17.2%
Rev Growth +6.2% +12.2% +11.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 34.63M 27.99M 31.26M
Total Equity 59.22M 51.92M 51.92M
D/E Ratio 0.58 0.54 0.60
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -13,281,170 -15,040,886 -15,866,697
Free Cash Flow -10,468,769 -13,384,851 -9,996,517